Φιλτράρισμα ανά Last updated date SelectΜετάΠρινFrom - To Date Ημερομηνία λήξης This week This month Last week Last month Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate usePRIMECareersMedication errorParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Leave this field blank Filter Αποτελέσματα (3839) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Leave this field blank Committee for Orphan Medicinal Products: January 2005 meeting 18 Ιανουάριος 2005Press releaseHumanRare diseases Committee for medicinal products for veterinary use: Meeting of 11-12 January 2005 13 Ιανουάριος 2005Press releaseVeterinary Important new pharmacokinetic data demonstrating that REYATAZ (atazanavirsulfate) combined with NORVIR (ritonavir) and omeprazole should not be co-administered 22 Δεκέμβριος 2004News European Medicines Agency statement on celecoxib 17 Δεκέμβριος 2004Press releaseMedicines Management Board finalises its long-term plan and adopts workprogramme and budget for 2005 17 Δεκέμβριος 2004Press releaseCorporate European Medicines Agency: Committee for Medicinal Products for Human Use 13-15 December 2004 16 Δεκέμβριος 2004Press releaseHumanMedicines European Medicines Agency public statement on valdecoxib and parecoxib sodium. Cardiovascular risks in coronary artery bypass graft surgery and serious adverse skin reactions 15 Δεκέμβριος 2004NewsMedicines Committee for medicinal products for veterinary use: Meeting of 7 to 9 December 2004 10 Δεκέμβριος 2004Press releaseVeterinary Committee for Orphan Medicinal Products: December 2004 meeting 10 Δεκέμβριος 2004Press releaseHumanRare diseases CHMP meeting on Paroxetine and other SSRIs 9 Δεκέμβριος 2004Press release 1 … 341 342 343 344 345 Page 345 of 384 346 347 348 349 … 384
Committee for Orphan Medicinal Products: January 2005 meeting 18 Ιανουάριος 2005Press releaseHumanRare diseases
Committee for medicinal products for veterinary use: Meeting of 11-12 January 2005 13 Ιανουάριος 2005Press releaseVeterinary
Important new pharmacokinetic data demonstrating that REYATAZ (atazanavirsulfate) combined with NORVIR (ritonavir) and omeprazole should not be co-administered 22 Δεκέμβριος 2004News
Management Board finalises its long-term plan and adopts workprogramme and budget for 2005 17 Δεκέμβριος 2004Press releaseCorporate
European Medicines Agency: Committee for Medicinal Products for Human Use 13-15 December 2004 16 Δεκέμβριος 2004Press releaseHumanMedicines
European Medicines Agency public statement on valdecoxib and parecoxib sodium. Cardiovascular risks in coronary artery bypass graft surgery and serious adverse skin reactions 15 Δεκέμβριος 2004NewsMedicines
Committee for medicinal products for veterinary use: Meeting of 7 to 9 December 2004 10 Δεκέμβριος 2004Press releaseVeterinary
Committee for Orphan Medicinal Products: December 2004 meeting 10 Δεκέμβριος 2004Press releaseHumanRare diseases